Researcher Profile

Researcher Profile

David Claxton, MD

David Claxton, MD

Professor, Department of Medicine
Division of Hematology and Oncology
Scientific Program:Next-Generation Therapies
Disease Teams:
Bone Marrow Transplantation
Leukemia and Lymphoma

Research Interests

Dr. David Claxton has longstanding interests in leukemia biology and therapeutics. Leukemia molecular genetics and diagnostics are ongoing interests. Acute myeloid leukemia and related disorders are his principal foci. Leukemia therapeutics are particular interests, including drug development and clinical studies, blood and marrow transplantation, and clinical supportive care. He has a laboratory which has banked many samples of human leukemias and lymphomas. These are viably cryopreserved, used in studies and available to collaborators.

  • Acute Myeloid Leukemia
  • Therapeutics
  • Leukemia
  • Neoplasms
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Genes
  • Bone Marrow
  • Drug Therapy
  • T-Lymphocytes
  • Proteins
  • Stem Cells
  • Transplants

Clinical Trials

Blood and Bone Marrow Collection from Patients with Hematological Malignancies for Study of Anti-Tumor Immunity
Clofarabine followed by Fludarabine, Busulfan, Total-Body Irradiation and Hematopoietic Stem Cell Transplant with Post-Transplant Cyclophosphamide for Non-remission Acute Myeloid Leukemia
A Phase Ib/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
EA9161: A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
Biologic Studies of Experimental Anti-Cancer Therapeutics in Human Leukemia Cells
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications
T-Cell Exhaustion in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia
Protocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation
Protocol for a Research Database for Hematopoietic Cell Transplantation, other Cellular Therapies and Marrow Toxic Injuries.

Recent Publications


Pearson, JM, Tan, SF, Sharma, A, Annageldiyev, C, Fox, TE, Abad, JL, Fabrias, G, Desai, D, Amin, S, Wang, HG, Cabot, MC, Claxton, DF, Kester, M, Feith, DJ & Loughran, TP 2020, 'Ceramide analogue SACLAC modulates sphingolipid levels and MCL-1 splicing to induce apoptosis in acute myeloid leukemia', Molecular Cancer Research, vol. 18, no. 3, pp. 352-363.
Annageldiyev, C, Gowda, K, Patel, T, Bhattacharya, P, Tan, SF, Iyer, S, Desai, D, Dovat, S, Feith, DJ, Loughran, TP, Amin, S, Claxton, D & Sharma, A 2020, 'The novel Isatin analog KS99 targets stemness markers in acute myeloid leukemia', Haematologica, vol. 105, no. 3, pp. 687-696.


Stock, W, Luger, SM, Advani, AS, Yin, J, Harvey, RC, Mullighan, CG, Willman, CL, Fulton, N, Laumann, KM, Malnassy, G, Paietta, E, Parker, E, Geyer, S, Mrózek, K, Bloomfield, CD, Sanford, B, Marcucci, G, Liedtke, M, Claxton, DF, Foster, MC, Bogart, JA, Grecula, JC, Appelbaum, FR, Erba, H, Litzow, MR, Tallman, MS, Stone, RM & Larson, RA 2019, 'A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: Results of CALGB 10403', Blood, vol. 133, no. 14, pp. 1548-1559.
Tan, SF, Dunton, W, Liu, X, Fox, TE, Morad, SAF, Desai, D, Doi, K, Conaway, MR, Amin, S, Claxton, DF, Wang, HG, Kester, M, Cabot, MC, Feith, DJ & Loughran, TP 2019, 'Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-κB-dependent P-glycoprotein upregulation', Journal of Lipid Research, vol. 60, no. 6, pp. 1078-1086.
Patel, TN, Madhunapantula, SRV, Annageldiyev, C, Claxton, D & Sharma, A 2019, Animal mouse models of acute myeloid leukemia. in A Azmi & RM Mohammad (eds), Animal Models in Cancer Drug Discovery. Academic Press, pp. 419-438. <>
Kao, LP, Morad, SAF, Davis, TS, MacDougall, MR, Kassai, M, Abdelmageed, N, Fox, TE, Kester, M, Loughran, TP, Abad, JL, Fabrias, G, Tan, SF, Feith, DJ, Claxton, DF, Spiegel, S, Fisher-Wellman, KH & Cabot, MC 2019, 'Chemotherapy selection pressure alters sphingolipid composition and mitochondrial bioenergetics in resistant HL-60 cells', Journal of Lipid Research, vol. 60, no. 9, pp. 1590-1602.
Kong, Y, Jia, B, Zhao, C, Claxton, DF, Sharma, A, Annageldiyev, C, Fotos, JS, Zeng, H, Paulson, RF, Prabhu, KS & Zheng, H 2019, 'Downregulation of CD73 associates with T cell exhaustion in AML patients', Journal of Hematology and Oncology, vol. 12, no. 1, 40.
Jia, B, Zhao, C, Rakszawski, KL, Claxton, DF, Christopher Ehmann, W, Rybka, WB, Mineishi, S, Wang, M, Shike, H, Bayerl, MG, Sivik, JM, Schell, TD, Drabick, JJ, Hohl, RJ & Zheng, H 2019, 'Eomes+T-betlow CD8+ T cells are functionally impaired and are associated with poor clinical outcome in patients with acute myeloid leukemia', Cancer Research, vol. 79, no. 7, pp. 1635-1645.
Pu, JJ, Poulose, J, Malysz, J, Zhu, J, Fanburg-Smith, JC, Claxton, DF & Bayerl, MG 2019, 'Impact of ruxolitinib on myelofibrosis patients post allogeneic stem cell transplant—a pilot study', British Journal of Haematology, vol. 186, no. 5, pp. e130-e133.
Zhao, C, Jia, B, Wang, M, Schell, TD, Claxton, DF, Ehmann, WC, Rybka, WB, Mineishi, S, Naik, S, Songdej, N, Sivik, JM, Hohl, RJ, Zeng, H & Zheng, H 2020, 'Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML', British Journal of Haematology, vol. 188, no. 5, pp. 674-684.
Kempin, S, Sun, Z, Kay, NE, Paietta, EM, Mazza, JJ, Ketterling, RP, Frankfurt, O, Claxton, DF, Saltzman, JN, Srkalovic, G, Callander, NS, Gross, G & Tallman, MS 2019, 'Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903)', Acta Haematologica, vol. 142, no. 4, pp. 224-232.
Spurgeon, SE, Sharma, K, Claxton, DF, Ehmann, C, Pu, J, Shimko, S, Stewart, A, Subbiah, N, Palmbach, G, LeBlanc, F, Latour, E, Chen, YY, Mori, M, Hasanali, Z & Epner, EM 2019, 'Phase 1–2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma', British Journal of Haematology, vol. 186, no. 6, pp. 845-854.
Barth, BM, Wang, W, Toran, PT, Fox, TE, Annageldiyev, C, Ondrasik, RM, Keasey, NR, Brown, TJ, Devine, VG, Sullivan, EC, Cote, AL, Papakotsi, V, Tan, SF, Shanmugavelandy, SS, Deering, TG, Needle, DB, Stern, ST, Zhu, J, Liao, J, Viny, AD, Feith, DJ, Levine, RL, Wang, HG, Loughran, TP, Sharma, A, Kester, M & Claxton, DF 2019, 'Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia', Blood Advances, vol. 3, no. 17, pp. 2598-2603.
Cioccio, J & Claxton, D 2019, 'Therapy of acute myeloid leukemia: therapeutic targeting of tyrosine kinases', Expert Opinion on Investigational Drugs, vol. 28, no. 4, pp. 337-349.


Jia, B, Wang, L, Claxton, DF, Ehmann, WC, Rybka, WB, Mineishi, S, Rizvi, S, Shike, H, Bayerl, M, Schell, TD, Hohl, RJ & Zheng, H 2018, 'Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients', Blood Cancer Journal, vol. 8, no. 3, 34.
Van De Louw, A, Desai, RJ, Zhu, J & Claxton, D 2018, 'Characteristics of early acute respiratory distress syndrome in newly diagnosed acute myeloid leukemia', Leukemia and Lymphoma, vol. 59, no. 10, pp. 2369-2376.
Rakszawski, KL, Miki, K, Claxton, D, Wagner, H, Shike, H, Mineishi, S & Naik, S 2018, 'Clofarabine followed by haploidentical stem cell transplant using fludarabine, busulfan, and total-body irradiation with post-transplant cyclophosphamide in non-remission AML', International journal of hematology, vol. 108, no. 3, pp. 348-350.
Kokolus, KM, Haley, JS, Koubek, EJ, Gowda, R, Dinavahi, SS, Sharma, A, Claxton, DF, Helm, KF, Drabick, JJ, Robertson, GP, Neighbors, JD, Hohl, RJ & Schell, TD 2019, 'Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity', OncoImmunology, vol. 8, no. 2, e1539614.
Prabhu, VV, Talekar, MK, Lulla, AR, Kline, CLB, Zhou, L, Hall, J, Van den Heuvel, APJ, Dicker, DT, Babar, J, Grupp, SA, Garnett, MJ, McDermott, U, Benes, CH, Pu, JJ, Claxton, DF, Khan, N, Oster, W, Allen, JE & El-Deiry, WS 2018, 'Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies', Cell Cycle, vol. 17, no. 4, pp. 468-478.
McGill, CM, Tomco, PL, Ondrasik, RM, Belknap, KC, Dwyer, GK, Quinlan, DJ, Kircher, TA, Andam, CP, Brown, TJ, Claxton, DF & Barth, BM 2018, 'Therapeutic effect of Northern Labrador tea extracts for acute myeloid leukemia', Phytotherapy Research, vol. 32, no. 8, pp. 1636-1641.
Mato, AR, Nabhan, C, Thompson, MC, Lamanna, N, Brander, DM, Hill, B, Howlett, C, Skarbnik, A, Cheson, BD, Zent, C, Pu, J, Kiselev, P, Goy, A, Claxton, D, Isaac, K, Kennard, KH, Timlin, C, Landsburg, D, Winter, A, Nasta, SD, Bachow, SH, Schuster, SJ, Dorsey, C, Svoboda, J, Barr, P & Ujjani, CS 2018, 'Toxicities and outcomes of 616 ibrutinib-treated patients in the united states: A real-world analysis', Haematologica, vol. 103, no. 5, pp. 874-879.
Wang, L, Jia, B, Claxton, DF, Ehmann, WC, Rybka, WB, Mineishi, S, Naik, S, Khawaja, MR, Sivik, J, Han, J, Hohl, RJ & Zheng, H 2018, 'VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML', OncoImmunology, vol. 7, no. 9, e1469594.


Zhu, L, Kong, Y, Zhang, J, Claxton, DF, Ehmann, WC, Rybka, WB, Palmisiano, ND, Wang, M, Jia, B, Bayerl, M, Schell, TD, Hohl, RJ, Zeng, H & Zheng, H 2017, 'Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia', Journal of Hematology and Oncology, vol. 10, no. 1, 124.
Salzberg, AC, Harris-Becker, A, Popova, EY, Keasey, N, Loughran, TP, Claxton, DF & Grigoryev, SA 2017, 'Genome-wide mapping of histone H3K9me2 in acute myeloid leukemia reveals large chromosomal domains associated with massive gene silencing and sites of genome instability', PloS one, vol. 12, no. 3, e0173723.
Schneider, C, Bayerl, M, Boyer, C, Desai, R, Claxton, D & Van De Louw, A 2017, 'Increased CD13 expression in acute myeloid leukemia-associated early acute hypoxic respiratory failure', American journal of respiratory and critical care medicine, vol. 196, no. 8, pp. 1077-1080.
Goldenberg, D, Joshi, M, Malysz, J, Claxton, D & Cottrill, EE 2017, 'Myeloid sarcoma of the thyroid', Ear, Nose and Throat Journal, vol. 96, no. 12, pp. 460-461.
Mato, AR, Hill, BT, Lamanna, N, Barr, PM, Ujjani, CS, Brander, DM, Howlett, C, Skarbnik, AP, Cheson, BD, Zent, CS, Pu, JJ, Kiselev, P, Foon, K, Lenhart, J, Henick Bachow, S, Winter, AM, Cruz, AL, Claxton, DF, Goy, A, Daniel, C, Isaac, K, Kennard, KH, Timlin, C, Fanning, M, Gashonia, L, Yacur, M, Svoboda, J, Schuster, SJ & Nabhan, C 2017, 'Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 28, no. 5, pp. 1050-1056.
Abendroth, MD, Bayerl, MG, Wilkinson, MJ, Claxton, DF & Specht, CS 2017, 'Orbital Epstein-Barr Virus-Positive Polymorphic B-Cell Lymphoproliferative Disorder in an Apparently Immunocompetent Woman', Ocular Oncology and Pathology, vol. 4, no. 1, pp. 61-65.
Teye, EK, Sido, A, Xin, P, Finnberg, NK, Gokare, P, Kawasawa, YI, Salzberg, AC, Shimko, S, Bayerl, M, Ehmann, WC, Claxton, DF, Rybka, WB, Drabick, JJ, Wang, HG, Abraham, T, El-Deiry, WS, Brodsky, RA, J.Hohl, R & Pu, JJ 2017, 'PIGN gene expression aberration is associated with genomic instability and leukemic progression in acute myeloid leukemia with myelodysplastic features', Oncotarget, vol. 8, no. 18, pp. 29887-29905.
Hengst, J, Dick, TE, Sharma, A, Doi, K, Hegde, S, Tan, SF, Geffert, L, Fox, TE, Sharma, AK, Desai, D, Amin, S, Kester, M, Loughran, TP, Paulson, R, Claxton, D, Wang, H-G & Yun, J 2017, 'SKI-178: A multitargeted inhibitor of sphingosine kinase and microtubule dynamics demonstrating therapeutic efficacy in acute myeloid leukemia models', Cancer Translational Medicine, vol. 3, no. 4, pp. 109-121.
Doshi, UA, Shaw, J, Fox, TE, Claxton, DF, Loughran, TP & Kester, M 2017, 'STAT3 mediates C6-ceramide-induced cell death in chronic lymphocytic leukemia', Signal Transduction and Targeted Therapy, vol. 2, e17051.
Perl, AE, Altman, JK, Cortes, J, Smith, C, Litzow, M, Baer, MR, Claxton, D, Erba, HP, Gill, S, Goldberg, S, Jurcic, JG, Larson, RA, Liu, C, Ritchie, E, Schiller, G, Spira, AI, Strickland, SA, Tibes, R, Ustun, C, Wang, ES, Stuart, R, Röllig, C, Neubauer, A, Martinelli, G, Bahceci, E & Levis, M 2017, 'Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study', The Lancet Oncology, vol. 18, no. 8, pp. 1061-1075.
Levy, MA & Claxton, D 2017, 'Therapeutic inhibition of BCL-2 and related family members', Expert Opinion on Investigational Drugs, vol. 26, no. 3, pp. 293-301.


Kirschbaum, MH, Frankel, P, Synold, TW, Zain, J, Claxton, D, Tuscano, J, Newman, EM, Gandara, DR & Lara, PN 2018, 'A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study', British Journal of Haematology, vol. 180, no. 3, pp. 445-448.
Tan, SF, Liu, X, Fox, TE, Barth, BM, Sharma, A, Turner, SD, Awwad, A, Dewey, A, Doi, K, Spitzer, B, Shah, MV, Morad, SAF, Desai, D, Amin, S, Zhu, J, Liao, J, Yun, J, Kester, M, Claxton, DF, Wang, HG, Cabot, MC, Schuchman, EH, Levine, RL, Feith, DJ & Loughran, TP 2016, 'Acid ceramidase is upregulated in AML and represents a novel therapeutic target', Oncotarget, vol. 7, no. 50, pp. 83208-83222.
Liu, Q, Chen, L, Atkinson, JM, Claxton, DF & Wang, HG 2016, 'Atg5-dependent autophagy contributes to the development of acute myeloid leukemia in an MLL-AF9-driven mouse model', Cell Death and Disease, vol. 7, no. 9, e2361.
Morad, SAF, Ryan, TE, Neufer, PD, Zeczycki, TN, Davis, TS, MacDougall, MR, Fox, TE, Tan, SF, Feith, DJ, Loughran, TP, Kester, M, Claxton, DF, Barth, BM, Deering, TG & Cabot, MC 2016, 'Ceramide-tamoxifen regimen targets bioenergetic elements in acute myelogenous leukemia', Journal of Lipid Research, vol. 57, no. 7, pp. 1231-1242.
Stefanski, M, Jamis-Dow, C, Bayerl, M, Desai, RJ, Claxton, DF & Van De Louw, A 2016, 'Chest radiographic and CT findings in hyperleukocytic acute myeloid leukemia A retrospective cohort study of 73 patients', Medicine (United States), vol. 95, no. 44, e5285.
Van de Louw, A, Desai, RJ, Schneider, CW & Claxton, DF 2016, 'Hypoxemia during extreme hyperleukocytosis: How spurious?', Respiratory care, vol. 61, no. 1, pp. 8-14.
Van De Louw, A, Schneider, CW, Desai, RJ & Claxton, D 2016, 'Initial respiratory status in hyperleukocytic acute myeloid leukemia: Prognostic significance and effect of leukapheresis', Leukemia and Lymphoma, vol. 57, no. 6, pp. 1319-1326.
Mato, AR, Nabhan, C, Barr, PM, Ujjani, CS, Hill, BT, Lamanna, N, Skarbnik, AP, Howlett, C, Pu, JJ, Sehgal, AR, Strelec, LE, Vandegrift, A, Fitzpatrick, DM, Zent, CS, Feldman, T, Goy, A, Claxton, DF, Bachow, SH, Kaur, G, Svoboda, J, Nasta, SD, Porter, D, Landsburg, DJ, Schuster, SJ, Cheson, BD, Kiselev, P & Evens, AM 2016, 'Outcomes of CLL patients treated with sequential kinase inhibitor therapy: A real world experience', Blood, vol. 128, no. 18, pp. 2199-2205.
Kong, Y, Zhu, L, Schell, TD, Zhang, J, Claxton, DF, Ehmann, WC, Rybka, WB, George, MR, Zeng, H & Zheng, H 2016, 'T-cell immunoglobulin and ITIM domain (TIGIT) associates with CD8+ T-cell exhaustion and poor clinical outcome in AML patients', Clinical Cancer Research, vol. 22, no. 12, pp. 3057-3066.

Clinical Trials Search

Children (age < 18 years)
Adults (age >= 18 years)